Factors influencing retention of adenovirus within tumours following direct intratumoural injection - PubMed (original) (raw)
doi: 10.1038/gt.2008.2. Epub 2008 Feb 21.
Affiliations
- PMID: 18288207
- DOI: 10.1038/gt.2008.2
Factors influencing retention of adenovirus within tumours following direct intratumoural injection
M Bazan-Peregrino et al. Gene Ther. 2008 May.
Abstract
Direct intratumoural (IT) administration of adenovirus is widely used, however little is known about the resulting distribution of virus particles. Here we have evaluated the influence of tumour size, volume of injectate and occlusion of injection sites (to prevent retrograde seepage) on particle biodistribution and transgene expression. In subcutaneous MDA-231 xenografts, IT injection of relatively large volumes (4 x 20% (vol/vol) injections) resulted in just 40% of the administered dose being retained in tumour tissue after 30 min, with 15% in the liver thought to reflect systemic 'overflow'. Occlusion of the injection sites using surgical adhesive increased retention of the vector to 80% in the tumour with no increase in liver levels. Spread of expression was enhanced using multiple injection sites, but not by using larger injectate volumes. In ZR75.1 breast carcinoma xenografts virus distribution was different, with no evidence of systemic overflow leading to hepatic transduction following IT injection. Typically, clinical doses employ up to 30% vol/vol IT injections. Depending on the tumour, this may give considerable systemic overflow and might account for the high frequency of fevers observed. Virus performance might be improved by tailoring volumes and frequency of IT injection for tumour biology or histotype.
Similar articles
- Intrahepatic injection of adenovirus reduces inflammation and increases gene transfer and therapeutic effect in mice.
Crettaz J, Berraondo P, Mauleón I, Ochoa-Callejero L, Shankar V, Barajas M, van Rooijen N, Kochanek S, Qian C, Prieto J, Hernández-Alcoceba R, González-Aseguinolaza G. Crettaz J, et al. Hepatology. 2006 Sep;44(3):623-32. doi: 10.1002/hep.21292. Hepatology. 2006. PMID: 16941711 - Extended plasma circulation time and decreased toxicity of polymer-coated adenovirus.
Green NK, Herbert CW, Hale SJ, Hale AB, Mautner V, Harkins R, Hermiston T, Ulbrich K, Fisher KD, Seymour LW. Green NK, et al. Gene Ther. 2004 Aug;11(16):1256-63. doi: 10.1038/sj.gt.3302295. Gene Ther. 2004. PMID: 15215884 - Adenovirus-mediated gene transfer to orthotopic hepatocellular carcinomas in athymic nude mice.
Yoon SK, Armentano D, Wands JR, Mohr L. Yoon SK, et al. Cancer Gene Ther. 2001 Aug;8(8):573-9. doi: 10.1038/sj.cgt.7700345. Cancer Gene Ther. 2001. PMID: 11571535 - Tumour-specific therapeutic adenovirus vectors: repression of transgene expression in healthy cells by endogenous p53.
Lipinski KS, Djeha AH, Krausz E, Lane DP, Searle PF, Mountain A, Wrighton CJ. Lipinski KS, et al. Gene Ther. 2001 Feb;8(4):274-81. doi: 10.1038/sj.gt.3301403. Gene Ther. 2001. PMID: 11313801 - Long-term gene transfer to mouse fetuses with recombinant adenovirus and adeno-associated virus (AAV) vectors.
Mitchell M, Jerebtsova M, Batshaw ML, Newman K, Ye X. Mitchell M, et al. Gene Ther. 2000 Dec;7(23):1986-92. doi: 10.1038/sj.gt.3301332. Gene Ther. 2000. PMID: 11175309
Cited by
- Oncolytic virotherapy in cancer treatment: challenges and optimization prospects.
Chen L, Zuo M, Zhou Q, Wang Y. Chen L, et al. Front Immunol. 2023 Dec 15;14:1308890. doi: 10.3389/fimmu.2023.1308890. eCollection 2023. Front Immunol. 2023. PMID: 38169820 Free PMC article. Review. - Efficient Intravenous Tumor Targeting Using the αvβ6 Integrin-Selective Precision Virotherapy Ad5NULL-A20.
Davies JA, Marlow G, Uusi-Kerttula HK, Seaton G, Piggott L, Badder LM, Clarkson RWE, Chester JD, Parker AL. Davies JA, et al. Viruses. 2021 May 8;13(5):864. doi: 10.3390/v13050864. Viruses. 2021. PMID: 34066836 Free PMC article. - Ultrasound-mediated oncolytic virus delivery and uptake for increased therapeutic efficacy: state of art.
Nande R, Howard CM, Claudio PP. Nande R, et al. Oncolytic Virother. 2015 Nov 25;4:193-205. doi: 10.2147/OV.S66097. eCollection 2015. Oncolytic Virother. 2015. PMID: 27512682 Free PMC article. Review. - Polymeric Cups for Cavitation-mediated Delivery of Oncolytic Vaccinia Virus.
Myers R, Coviello C, Erbs P, Foloppe J, Rowe C, Kwan J, Crake C, Finn S, Jackson E, Balloul JM, Story C, Coussios C, Carlisle R. Myers R, et al. Mol Ther. 2016 Sep;24(9):1627-33. doi: 10.1038/mt.2016.139. Epub 2016 Jul 4. Mol Ther. 2016. PMID: 27375160 Free PMC article. - Phase I dose-escalating trial of Escherichia coli purine nucleoside phosphorylase and fludarabine gene therapy for advanced solid tumors.
Rosenthal EL, Chung TK, Parker WB, Allan PW, Clemons L, Lowman D, Hong J, Hunt FR, Richman J, Conry RM, Mannion K, Carroll WR, Nabell L, Sorscher EJ. Rosenthal EL, et al. Ann Oncol. 2015 Jul;26(7):1481-7. doi: 10.1093/annonc/mdv196. Epub 2015 Apr 21. Ann Oncol. 2015. PMID: 25899782 Free PMC article. Clinical Trial.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical